Research Article

PR+ breast cancer stem cells

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India

Search for more papers by this author

Chinmay Das

https://orcid.org/0000-0003-2144-667X

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India

Search for more papers by this author

Biswajit Das

https://orcid.org/0000-0002-9112-0600

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India

Search for more papers by this author

Atala Bihari Jena

https://orcid.org/0000-0002-1690-7913

National Centre for Cell Science (NCCS), Savitribai Phule Pune University Campus, Ganeshkhind, Pune, India

Search for more papers by this author

Subarno Paul

https://orcid.org/0000-0003-4290-7084

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India

Search for more papers by this author

Saptarshi Sinha

https://orcid.org/0000-0003-0687-924X

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India

Search for more papers by this author

Jasaswini Tripathy

School of Applied Sciences (Chemistry), Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India

Search for more papers by this author

Chanakya Nath Kundu

*Author for correspondence: Tel.: +91 0674 272 5466;

E-mail Address: cnkundu@kiitbiotech.ac.in

https://orcid.org/0000-0003-0297-1030

Cancer Biology Division, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha, 751024, India

Search for more papers by this author

Published Online:31 Jan 2024https://doi.org/10.2217/nnm-2023-0269

View article

Abstract

Aim: This study aimed to determine if quinacrine–gold hybrid nanoparticles (QAuNPs) + near-infrared (NIR) deregulate HSP-70/P300 complex-mediated H3K14 acetylation in estrogen receptor/progesterone receptor (ER/PR+) breast cancer stem cells (CSCs). Materials & methods: Various cells and mouse-based systems were used as models. Results: QAuNP + NIR treatment reduced the nuclear translocation of HSP-70, affected the histone acetyltransferase activity of P300 and specifically decreased H3K14 acetylation in ER/PR+ breast CSCs. Finally, HSP-70 knockdown showed a reduction in P300 histone acetyltransferase activity, decreased H3K14 acetylation and inhibited activation of the TGF-β gene. Conclusion: This study revealed that QAuNP + NIR irradiation inhibits oncogenic activation of the TGF-β gene by decreasing H3K14 acetylation mediated through the HSP-70/P300 nuclear complex in ER/PR+ breast CSCs.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Prud'Homme GJ. Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest. 87(11), 1077–1091 (2007).
MedlineGoogle Scholar
2. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β – an excellent servant but a bad master. J. Transl. Med. 10, 183 (2012). • Highlights the role of TGF-β in cancer development and progression.
Medline CASGoogle Scholar
3. Seoane J, Gomis RR. TGF-β family signaling in tumor suppression and cancer progression. Cold Spring Harb. Perspect. Biol. 9(12), a022277 (2017).
MedlineGoogle Scholar
4. Papageorgis P, Stylianopoulos T. Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review). Int. J. Oncol. 46(3), 933–943 (2015).
Medline CASGoogle Scholar
5. Lu Y, Chan Y-T, Tan H-Y, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol. Cancer 19(1), 79 (2020). • Highlights how epigenetic modification regulates the activation of oncogenes.
MedlineGoogle Scholar
6. Bure IV, Nemtsova MV, Kuznetsova EB. Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis. Int. J. Mol. Sci. 23(10), 5801 (2022).
Medline CASGoogle Scholar
7. Tzavlaki K, Moustakas A. TGF-β signaling. Biomolecules 10(3), 487 (2020).
Medline CASGoogle Scholar
8. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 21(3), 381–395 (2011).
Medline CASGoogle Scholar
9. Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J. Natl Cancer Center 2(4), 277–290 (2022).
Google Scholar
10. Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics 12(11), 4935–4948 (2022).
Medline CASGoogle Scholar
11. Kimura H. Histone modifications for human epigenome analysis. J. Hum. Genet. 58(7), 439–445 (2013).
Medline CASGoogle Scholar
12. Armenta-Castro E, Reyes-Vallejo T, Máximo-Sánchez D et al. Histone H3K9 and H3K14 acetylation at the promoter of the LGALS9 gene is associated with mRNA levels in cervical cancer cells. FEBS Open Bio. 10(11), 2305–2315 (2020).
Medline CASGoogle Scholar
13. Toh TB, Lim JJ, Chow EK-H. Epigenetics in cancer stem cells. Mol. Cancer 16(1), 29 (2017).
MedlineGoogle Scholar
14. Paul S, Sinha S, Kundu CN. Targeting cancer stem cells in the tumor microenvironment: an emerging role of PARP inhibitors. Pharmacol. Res. 184, 106425 (2022).
Medline CASGoogle Scholar
15. Sinha S, Molla S, Kundu CN. PARP1-modulated chromatin remodeling is a new target for cancer treatment. Med. Oncol. 38(10), 118 (2021).
Medline CASGoogle Scholar
16. Mayer MP, Bukau B. HSP70 chaperones: cellular functions and molecular mechanism. Cell Mol. Life Sci. 62(6), 670–684 (2005).
Medline CASGoogle Scholar
17. Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM. HSP70 multi-functionality in cancer. Cells 9(3), 587 (2020). • First to show that deregulating the HSP-70/TGF-β axis with quinacrine-gold hybrid nanoparticle and near-infrared irradiation suppresses angiogenesis in breast cancer.
Medline CASGoogle Scholar
18. Dash SR, Das B, Das C et al. Near-infrared enhances antiangiogenic potentiality of quinacrine-gold hybrid nanoparticles in breast cancer stem cells via deregulation of HSP-70/TGF-β. Nanomedicine (Lond.) 18(1), 19–33 (2023). • First to demonstrate that the combination of quinacrine-gold hybrid nanoparticle and near-infrared can reduce the ability of oral cancer stem cells to metastasize.
CASGoogle Scholar
19. Dash SR, Chatterjee S, Sinha S et al. NIR irradiation enhances the apoptotic potentiality of quinacrine-gold hybrid nanoparticles by modulation of HSP-70 in oral cancer stem cells. Nanomedicine 40, 102502 (2022).
Medline CASGoogle Scholar
20. Satapathy SR, Nayak A, Siddharth S, Das S, Nayak D, Kundu CN. Metallic gold and bioactive quinacrine hybrid nanoparticles inhibit oral cancer stem cell and angiogenesis by deregulating inflammatory cytokines in p53 dependent manner. Nanomedicine 14(3), 883–896 (2018).
Medline CASGoogle Scholar
21. Kamal KM, Narayan R, Chandran N et al. Synergistic enhancement of photocatalytic CO₂ reduction by plasmonic Au nanoparticles on TiO₂ decorated N-graphene heterostructure catalyst for high selectivity methane production. Appl. Catalysis B. Environ. 307, 121181 (2022).
CASGoogle Scholar
22. Ambrožič B, Prašnikar A, Hodnik N et al. Controlling the radical-induced redox chemistry inside a liquid-cell TEM. Chem. Sci. 10(38), 8735–8743 (2019).
Medline CASGoogle Scholar
23. Das B, Sethy C, Chatterjee S et al. Quinacrine inhibits cMET-mediated metastasis and angiogenesis in breast cancer stem cells. J. Cell Commun. Signal. 17, 1371–1388 (2023).
Medline CASGoogle Scholar
24. Hembram KC, Dash SR, Das B et al. Quinacrine based gold hybrid nanoparticles caused apoptosis through modulating replication fork in oral cancer stem cells. Mol. Pharm. 17(7), 2463–2472 (2020).
Medline CASGoogle Scholar
25. Sinha S, Chatterjee S, Paul S et al. Olaparib enhances the resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway. Exp. Cell Res. 420(1), 113338 (2022).
Medline CASGoogle Scholar
26. Paul S, Chatterjee S, Sinha S et al. Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells. Expert Opin. Ther. Targets 27(10), 999–1015 (2023).
Medline CASGoogle Scholar
27. Molla S, Chatterjee S, Sethy C, Sinha S, Kundu CN. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly. DNA Repair (Amst.) 105, 103157 (2021).
Medline CASGoogle Scholar
28. Chatterjee S, Dhal AK, Paul S et al. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping. J. Cancer Res. Clin. Oncol. 148(12), 3521–3535 (2022).
Medline CASGoogle Scholar
29. Das C, Dash SR, Sinha S et al. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300. Med. Oncol. 40(12), 351 (2023).
Medline CASGoogle Scholar
30. Kozakov D, Hall DR, Xia B et al. The ClusPro web server for protein-protein docking. Nat. Protoc. 12(2), 255–278 (2017).
Medline CASGoogle Scholar
31. Jena AB, Kanungo N, Nayak V, Chainy GBN, Dandapat J. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies. Sci. Rep. 11(1), 2043 (2021).
Medline CASGoogle Scholar
32. Pradhan R, Paul S, Das B et al. Resveratrol nanoparticle attenuates metastasis and angiogenesis by deregulating inflammatory cytokines through inhibition of CAFs in oral cancer by CXCL-12/IL-6-dependent pathway. J. Nutr. Biochem. 113, 109257 (2023).
Medline CASGoogle Scholar
33. Sethy C, Goutam K, Das B, Dash SR, Kundu CN. Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis. Vascul. Pharmacol. 140, 106865 (2021).
Medline CASGoogle Scholar
34. Wang F, Marshall CB, Ikura M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell. Mol. Life Sci. 70(21), 3989–4008 (2013).
Medline CASGoogle Scholar
35. Jena AB, Duttaroy AK. A computational approach for molecular characterization of covaxin (BBV152) and its ingredients for assessing its efficacy against COVID-19. Future Pharmacol. 2(3), 306–319 (2022).
Google Scholar
36. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 4, 51 (2011).
Medline CASGoogle Scholar
37. Verdone L, Agricola E, Caserta M, Di Mauro E. Histone acetylation in gene regulation. Brief. Funct. Genom. 5(3), 209–221 (2006).
CASGoogle Scholar
38. Wapenaar H, Dekker FJ. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin. Epigenet. 8(1), 59 (2016).
MedlineGoogle Scholar

Vol. 19, No. 7

Metrics

Downloaded 35 times

History

Received 25 September 2023

Accepted 22 December 2023

Published online 31 January 2024

Published in print March 2024

Information

Keywords

Author contributions

SR Dash: Conceptualization, methodology, investigation, validation, visualization, writing – original draft, writing – review and editing. C Das: Formal analysis, validation, visualization, methodology. B Das: Formal analysis, validation, visualization, methodology. AB Jena: Methodology, investigation, validation, visualization, writing – review and editing. S Paul: Resources, methodology. S Sinha: Formal analysis, validation. J Tripathy: Funding acquisition, formal analysis. CN Kundu: Conceptualization, methodology, investigation, validation, visualization, project administration, supervision, funding acquisition, writing – review and editing.

Financial disclosure

This work was financially supported by the Department of Science and Technology (DST) INSPIRE, Indian Council of Medical Research (ICMR; ref no. 5/13/57/2015/-NCD-III) and the Department of Atomic Energy-Board of Research in Nuclear Sciences (DAE-BRNS; ref. no. 35/14/01/2018-BRNS/35006). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all animal experimental investigations.

PDF download